期刊文献+

基于药效团模型的乙酰胆碱酯酶、聚腺苷二磷酸核糖聚合酶-1双靶点分子设计研究

Pharmacophore identification of novel dual-target compounds targeting AChE and PARP-1
原文传递
导出
摘要 本研究建立了乙酰胆碱酯酶(AChE)和聚腺苷二磷酸核糖聚合酶-1(PARP-1)抑制剂的药效团模型,设计、筛选了双靶点活性分子,并验证了其抑制活性,探讨了多靶点分子的设计策略。利用Catalyst计算机辅助药物设计软件系统,以叠合程度和构象能进行筛选,得到具有AChE、PARP-1抑制活性的双靶点结构。通过计算机预测目标分子的理化性质,得到5个优选的氨基噻唑类衍生物。将匹配的优选化合物合成后进行对AChE和PARP-1的抑制活性的实验验证。其中化合物3对AChE的抑制活性IC50为(0.337±0.052)μmol·L-1,而在1μmol·L-1浓度下对PARP-1的抑制率为24.6%。证明药效团模型在多靶点药物设计和筛选中能起到减少盲目性和加快设计开发的作用。 Multi-target drugs attract increasing attentions for the therapy of complicated neurodegenerative diseases. In this study, a computer-assisted strategy was applied to search for multi-target compounds by the pharmacophore matching. This strategy has been successfully used to design dual-target inhibitor models against both the acetylcholinesterase (ACHE) and poly (ADP-ribose) polymerase-1 (PARP-1). Based on two pharmacophore models matching and physicochemical properties filtering, one hit was identified which could inhibit AChE with IC50 value of (0.3374±0.052) μmol·L-1 and PARP-1 by 24.6% at 1 μmol·L-1.
出处 《药学学报》 CAS CSCD 北大核心 2014年第6期819-823,共5页 Acta Pharmaceutica Sinica
基金 国家重点基础研究发展计划(973计划)资助项目(2013CB531303) 科技部国际合作项目(2011DFA32670) 国家新药创制重大专项(2012ZX0913-101-045)
关键词 药效团模型 药物设计 多靶点药物 AChE抑制剂 PARP-1抑制剂 3D-pharmacophore modeling drug design multi-target drug acetylcholinesterase inhibitor poly (ADP- ribose) polymerase-1 inhibitor
  • 相关文献

参考文献2

二级参考文献42

  • 1Lucio T,Ilaria P,Grazia G.Potential clinical applications of poly(ADP-Ribose) polymerase (PARP) inhibitors[J].Pharmacol Res,2002,45:73-85.
  • 2Ha HC,Snyder SH.Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion[J].Proc Natl Acad Sci USA,1999,96:13978-13982.
  • 3Gabriele C,Antonio M,Emidio C,et al.Modeling of poly(ADP-ribose) polymerase (PARP) inhibitors.Docking of ligands and quantitative structure-activity relationship analysis[J].J Med Chem,2001,44:3786-3794.
  • 4Xu XJ,Hou TJ,Qiao XB,et al.Computer-Aided Drug Design (计算机辅助药物分子设计)[M].Beijing:Chemical Industry Press,2004:295.
  • 5Ferraris D,Ficco RP,Dain D,et al.Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors.Part 4:Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries[J].Bioorg Med Chem,2003,11:3695-3707.
  • 6Ishida J,Hattori K,Yamamoto H,et al.4-Phenyl-1,2,3,6-tetrahydropyridine,an excellent fragment to improve the potency of PARP-1 inhibitors[J].Bioorg Med Chem Lett,2005,15:4221-4225.
  • 7Iwashitaa A,Hattorib K,Yamamoto H,et al.Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors[J].FEBS Lett,2005,579:1389-1393.
  • 8Steinhagen H,Gerisch M,Mittendorf J,et al.Substituted uracil derivatives as potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)[J].Bioorg Med Chem Lett,2002,12:3187-3190.
  • 9Jagtap PG,Southan GJ,Baloglu E,et al.The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones:potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)[J].Bioorg Med Chem Lett,2004,14:81-85.
  • 10Loh VM,Cockcroft X,Dillon KJ,et al.Phthalazinones.Part 1:the design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose) polymerase[J].Bioorg Med Chem Lett,2005,15:2235-2238.

共引文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部